UA-145931898-1

T-Cell Therapy Market Opportunities, Top Manufactures, Industry Growth, Share, Size, Regional Analysis and Global Foreca

Comments · 356 Views

The global T-cell therapy market size is expected to reach USD 21 Billion in 2028 and register a CAGR of 20.4% over the forecast period, according to the latest report by Reports and Data.

 

Major prevalence of cancer and rising awareness regarding advanced cancer treatments are some of the key factors driving market revenue growth

The global T-cell therapy market size is expected to reach USD 21 Billion in 2028 and register a CAGR of 20.4% over the forecast period, according to the latest report by Reports and Data. Key factors such as increasing geriatric population globally, rising awareness about advanced cancer treatments, and major prevalence of cancers are driving market revenue growth. T-cell therapy is a type of immunotherapy that involves genetic modification of T-cells. This process is used to treat different types of cancers.

There are mainly three main types of T-cell therapies; CAR T-cell therapy, T-cell receptor (TCR)-based, and tumor infiltrating lymphocytes (TIL)-based. CAR T-cell therapy or Chimeric Antigen Receptor T-cell therapy is one of the most effective methods of cancer treatment. CAR T-cell therapy segment accounted for majority revenue share in the global market in 2020. This can be attributed to increasing number of clinical trials for CAR T-cell therapy and increasing investment in research related to CAR T-cell therapy.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2508

The rapid adoption of AI, ML, and IoT and robust data management processes has made the hospitals and clinical settings smarter. New technologies and solutions have improved the normal medical processes such as clinical diagnosis, treatment, diseases management, and monitoring patient recovery after discharge. Rapid digitalization and increasing adoption of virtual care and telemedicine is further expected to positively impact the revenue growth of the market going ahead.

Emergence of new healthcare and telemedicine startups, increasing number of collaborations among healthcare facilities and research institutions, and rising focus on patient engagement solutions has further fueled revenue growth of the market. Key companies are forming strategic alliances and collaborative ventures such as mergers and acquisitions, joint ventures, partnerships, manufacturing and licensing agreements, and product launches among others.

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2508

Leading Players Analyzed in the Report:

Novartis AG, Merck KGaA, Gilead Sciences Inc., TCR2 Therapeutics Inc., Bluebird Bio Inc., Sorrento Therapeutics, Fate Therapeutics, Pfizer Inc., Amgen, and Celgene Corporation.

Furthermore, to offer a better understanding of the competitive landscape, an extensive SWOT analysis and Porter’s Five Forces analysis are included in the report. Along with this, feasibility analysis and investment return analysis are also covered in the report.

The report further discusses in detail the regional spread of the global T-Cell Therapy market along with analysis of production and consumption patterns, import/export analysis, supply and demand ratio, market share and size based on volume and value, trends and demands, revenue share, and presence of the key players of the market.

To know more about the report @ https://www.reportsanddata.com/report-detail/t-cell-therapy-market

Key Regions Studied in the Report:

  • North America (U.S., Canada, Mexico)
  • Europe (U.K., Italy, Germany, France, Rest of Europe)
  • Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
  • Latin America (Chile, Brazil, Argentina, Rest of Latin America)
  • Middle East Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Modality Outlook (Revenue, USD Billion; 2018-2028)

  • Research
  • Commercialized

Therapy Outlook (Revenue, USD Billion; 2018-2028)

  • CAR T-cell therapy
  • T-cell receptor (TCR)-based
  • Tumor infiltrating lymphocytes (TIL)-based

Indication Outlook (Revenue, USD Billion; 2018-2028)

  • Hematologic Malignancies
  • Lymphoma
  • Myeloma
  • Leukemia
  • Solid Tumors
  • Brain Central Nervous System
  • Liver Cancer
  • Melanoma
  • Others

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2508

Thank you for reading our report. To know more about the customization of the report or further query about the report, please get in touch with us. Our team will ensure the report is well suited to your requirements. 

Browse More Reports:

Cardiac Care Medical Equipment Market @ https://www.reportsanddata.com/report-detail/cardiac-care-medical-equipment-market

Urinary Stone Treatment Device Market @ https://www.reportsanddata.com/report-detail/urinary-stone-treatment-devices-market

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:                                        

John W

Head of Business Development

Reports and Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com

 

 

               

Comments